Verinurad, a selective URAT1 inhibitor, in combination with febuxostat reduced albuminuria by approximately 50% in patients with type 2 diabetes mellitus although it is unknown whether this effect was solely attributed to the inhibition of urate reabsorption34. This evidence concerns the gene SLC22A12 and type 2 diabetes mellitus.